Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 October 2009, Vol. 114, No. 14, pp. 2945-2951.
Prepublished online as a Blood First Edition Paper on August 7, 2009; DOI 10.1182/blood-2009-02-204842.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Figures
Right arrow All Versions of this Article:
blood-2009-02-204842v1
114/14/2945    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Navarro, A.
Right arrow Articles by Monzo, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Navarro, A.
Right arrow Articles by Monzo, M.
Related Collections
Right arrow Lymphoid Neoplasia
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

LYMPHOID NEOPLASIA

Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma

Alfons Navarro1, Tania Diaz1, Antonio Martinez2, Anna Gaya3, Aina Pons1, Bernat Gel4, Carles Codony3, Gerardo Ferrer5, Carmen Martinez3, Emili Montserrat3, and Mariano Monzo1

1 Human Anatomy Unit, Molecular Oncology and Embryology Laboratory, University of Barcelona Medical School, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; 2 Hematopathology Section, Laboratory of Pathology and 3 Institute of Hematology and Oncology, Hospital Clinic, IDIBAPS, Barcelona; 4 Software Department, Universitat Politecnica de Catalunya, Barcelona; and 5 Institute of Hematology and Oncology, Laboratory of Translational Hematology, Hospital Clinic, IDIBAPS, Barcelona, Spain

The behavior of classic Hodgkin lymphoma (cHL) is determined by both the intrinsic features of the tumor cells and the characteristics of the microenvironment, making the analysis of entire lymph nodes an effective approach to understanding the disease. We examined the influence of our previously reported 25-microRNA signature for cHL on clinical outcome in 89 homogeneously treated cHL patients with a median follow-up of 80 months. Patients with low miR-135a expression had a higher probability of relapse (P = .04) and a shorter disease-free survival (P = .02). Functional analysis of cHL cell lines showed that mature miR-135a levels increased after pre–miR-135a transfection, causing apoptosis and decreased cell growth. Target analysis showed a direct regulation by miR-135a of JAK2, a cytoplasmic tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. miR-135a–mediated JAK2 down-regulation led to decreased mRNA and protein levels of the antiapoptotic gene Bcl-xL, suggesting a role for Bcl-xL in miR-135a/JAK2–mediated apoptosis. Our findings confirm the critical role of miR-135a in the survival of cHL cells and in the prognosis of cHL patients, indicating that novel treatment approaches targeting miR-135a may potentially benefit these patients.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020